The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 17, 2017

Filed:

Mar. 17, 2014
Applicants:

Whitehead Institute for Biomedical Research, Cambridge, MA (US);

Massachusetts Institute of Technology, Cambridge, MA (US);

Inventors:

Susan L. Lindquist, Cambridge, MA (US);

Stephen L. Buchwald, Newton, MA (US);

Daniel Tardiff, Arlington, MA (US);

Nathan Jui, Cambridge, MA (US);

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 235/04 (2006.01); A61K 31/4184 (2006.01); C07D 235/16 (2006.01); A61K 45/06 (2006.01); A61K 31/4439 (2006.01); C07D 235/08 (2006.01); C07D 401/12 (2006.01); C07D 403/04 (2006.01); C07D 405/04 (2006.01); C07D 409/12 (2006.01);
U.S. Cl.
CPC ...
C07D 235/16 (2013.01); A61K 31/4184 (2013.01); A61K 31/4439 (2013.01); A61K 45/06 (2013.01); C07D 235/08 (2013.01); C07D 401/12 (2013.01); C07D 403/04 (2013.01); C07D 405/04 (2013.01); C07D 409/12 (2013.01);
Abstract

The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and pharmaceutical compositions thereof. The present invention also provides methods and kits using the inventive compounds and pharmaceutical compositions for treating and/or preventing diseases associated with protein aggregation, such as amyloidoses (e.g., Parkinson's disease and Alzheimer's disease), treating and/or preventing neurodegenerative diseases, treating and/or preventing diseases associated with Tar DNA binding protein 43 kDa, reducing or preventing protein aggregation, and/or modulating E3 ubiquitin ligase in a subject in need thereof.


Find Patent Forward Citations

Loading…